Coût–efficacité de la résection transurétrale de vessie en lumière bleue chez les patients atteints d’un cancer de la vessie non infiltrant en France

Rouprêt, Morgan; Malavaud, Bernard; Molinier, Laurent; Leleu, Henri; Blachier, M.; Marteau, Florence

doi:10.1016/j.purol.2015.01.004

Cited by 15 publications

(2 citation statements)

References 21 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The findings of this study are in line with previous results of models for the cost-utility analysis of BL-TURB. Here, higher or similar initial costs of BL-TURB compared to WL-TURB are predicted which are compensated by cost benefits in the long term due to improved patient outcomes [20][21][22][23]. In a Markov model calculated for Germany, additional initial BL-TURB reduced costs by EUR 537 per patient compared to only WL-TURB.…”

Section: Discussionmentioning

confidence: 99%

“…The quality of the initial TURB, however, impacts prognosis and thereby also treatment costs. Models evaluating cost-effectiveness of BL-compared to WL-TURB predict increased quality-adjusted life years and lower long-term costs for BL-TURB despite BL-TURB being more expensive than WL-TURB [20][21][22][23]. So far there is only limited information available concerning initial use of WL-or BL-TURB.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Retrospective German claims data study on initial treatment of bladder carcinoma (BCa) by transurethral bladder resection (TURB): a comparative analysis of costs using standard white light- (WL-) vs. blue light- (BL-) TURB

Todenhöfer

Maas

Ketz³

et al. 2021

World J Urol

View full text Add to dashboard Cite

Purpose Photodynamic diagnosis using hexaminolevulinate (HAL)—guided BL-TURB may reduce the recurrence risk in non-muscle invasive BCa compared to standard WL-TURB due to more sensitive tumor detection. The impact of the initial use of WL- vs. BL-TURB on follow-up costs was evaluated in this real-world data analysis. Methods Anonymous claims data of German statutory health insurances (GKV) from 2011 to 2016 were analyzed in a primary and adjusted study population. Selection criteria included five quarters before enrolment, one index quarter (InQ) of initial TURB and BCa diagnosis, either within two years for the primary analysis or within four years for the adjusted analysis, and a follow-up period (FU) of either eleven or three quarters, respectively. Results In the primary analysis (n = 2331), cystectomy was identified as an important cost driver masking potential differences between cohorts. Therefore, patients undergoing cystectomy (InQ + FU) were excluded from the adjusted study population of n = 4541 patients (WL: 79%; BL: 21%). Mean total costs of BL-TURB were initially comparable to WL-TURB (WL: EUR 4534 vs. BL: EUR 4543) and tended to be lower compared to WL-TURB in the first two quarters of FU. After one year (3rd FU quarter), costs equalized. Considering total FU, mean costs of BL-TURB were significantly lower compared to WL-TURB (WL: EUR 7073 vs BL: EUR 6431; p = 0.045). Conclusion This retrospective analysis of healthcare claims data highlights the comparability of costs between BL-TURB and WL-TURB.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Retrospective German claims data study on initial treatment of bladder carcinoma (BCa) by transurethral bladder resection (TURB): a comparative analysis of costs using standard white light- (WL-) vs. blue light- (BL-) TURB

Todenhöfer

Maas

Ketz³

et al. 2021

World J Urol

View full text Add to dashboard Cite

show abstract

Kosten-Effektivitäts-Analyse zur Verwendung der Blaulichtzystoskopie mit Hexylaminolevulinat bei der transurethralen Resektion der Harnblase

Gakis

Volkmer

Qvick

et al. 2018

Urologe

View full text Add to dashboard Cite

show abstract

Optimised photodynamic diagnosis for transurethral resection of the bladder (TURB) in German clinical practice: results of the noninterventional study OPTIC III

et al. 2016

View full text Add to dashboard Cite

PurposeWhite light cystoscopy (WLC) is the standard procedure for visualising non-muscle invasive bladder cancer (NMIBC). However, WLC can fail to detect all cancerous lesions, and outcomes with transurethral resection of the bladder differ between institutions, controlled trials, and possibly between trials and routine application. This noninterventional study assessed the benefit of hexaminolevulinate blue light cystoscopy (HALC; Hexvix®, Ipsen Pharma GmbH, Germany) plus WLC versus WLC alone in routine use.MethodsFrom May 2013 to April 2014, 403 patients with suspected NMIBC were screened from 30 German centres to perform an unprecedented detailed assessment of the additional detection of cancer lesions with HALC versus WLC alone.ResultsAmong the histological results for 929 biopsy samples, 94.3 % were obtained from suspected cancerous lesions under either WLC or HALC: 59.5 % were carcinoma tissue and 40.5 % were non-cancerous tissue. Of all cancer lesions, 62.2 % were staged as Ta, 20.1 % as T1, 9.3 % as T2, 7.3 % as carcinoma in situ (CIS), and 1.2 % were unknown. Additional cancer lesions (+6.8 %) and CIS lesions (+25 %, p < 0.0001) were detected by HALC plus WLC versus WLC alone. In 10.0 % of patients, ≥1 additional positive lesion was detected with HALC, and 2.2 % of NMIBC patients would have been missed with WLC alone. No adverse events were observed.ConclusionsThe results of this study demonstrate that HALC significantly improves the detection of NMIBC versus WLC alone in routine clinical practice in Germany. While this benefit is statistically significant across all types of NMIBC, it seems most relevant in CIS.

show abstract

Coût–efficacité de la résection transurétrale de vessie en lumière bleue chez les patients atteints d’un cancer de la vessie non infiltrant en France

Cited by 15 publications

References 21 publications

Retrospective German claims data study on initial treatment of bladder carcinoma (BCa) by transurethral bladder resection (TURB): a comparative analysis of costs using standard white light- (WL-) vs. blue light- (BL-) TURB

Retrospective German claims data study on initial treatment of bladder carcinoma (BCa) by transurethral bladder resection (TURB): a comparative analysis of costs using standard white light- (WL-) vs. blue light- (BL-) TURB

Kosten-Effektivitäts-Analyse zur Verwendung der Blaulichtzystoskopie mit Hexylaminolevulinat bei der transurethralen Resektion der Harnblase

Optimised photodynamic diagnosis for transurethral resection of the bladder (TURB) in German clinical practice: results of the noninterventional study OPTIC III

Contact Info

Product

Resources

About